Every material Form 8-K EUDA Health Holdings Ltd has filed with the SEC since May 26, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
EUDA Health Holdings said Nasdaq told it on June 13, 2023 that it regained compliance with Listing Rule 5635(c) after CEO Dr. Kelvin Chen agreed to forfeit 271,867 of 850,306 shares issued to him in a loan settlement. Separately, Nasdaq accepted the company's plan to regain compliance with its late-filing rule, provided it files overdue reports by August 4, 2023, or faces possible delisting.
Chen received 850,306 restricted shares at $1.00 each to settle $850,306 in loans; the issue was priced below the $1.47 prior closing bid, which required shareholder approval.
Under a June 8, 2023 Supplemental Agreement, Chen forfeited 271,867 shares, leaving an effective issue price of $1.47 per share.
The company must file its delinquent 10-K and 10-Q by August 4, 2023; failure could lead to a delisting notice and appeal to a Nasdaq Hearings Panel.
EUDA amended its prepaid forward agreements with institutional investors on June 8, 2023, accelerating the maturity date. As a result, 1.6 million ordinary shares became immediately due to the sellers, and the sellers became entitled to retain the remaining prepayment from the trust account and the remaining shares. The share issuance adds to the existing share count and could dilute current shareholders, and the filing also reports a board change and a revised settlement with CEO Dr. Kelvin Chen.
1.6 million ordinary shares issuable as Maturity Consideration, 800,000 to each of two sellers, HB Strategies LLC and Alto Opportunity Master Fund, SPC
Maturity Date accelerated to June 8, 2023; the sellers may retain the remaining prepayment from EUDA's trust account and remaining shares
Sellers received registration rights and may not sell more than 15% of the daily trading volume on any exchange business day
Alfred Lim was appointed Executive Director on June 6, 2023 and resigned from three board committee roles
EUDA Health Holdings issued 2,317,606 restricted shares on May 16, 2023, to settle debts owed to a major shareholder, its CEO and related companies, and converted a $700,000 note into 700,000 shares. Between May 16 and May 22, 2023, it also sold 940,000 shares at $1.00 each to eight accredited investors for $940,000, which adds to the outstanding share count.
1,617,606 shares issued May 16, 2023, under five settlement agreements, including 850,306 shares to CEO Kelvin Chen to satisfy a $850,306 claim.
700,000 shares issued May 16, 2023, after James Tan converted a $700,000 note at $1.00 per share.
940,000 shares sold at $1.00 each, for $940,000, to eight accredited investors between May 16 and May 22, 2023.
None of the shares are registered under the Securities Act; the company agreed to register resale of the placement shares under registration rights agreements.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every EUDA Health Holdings Ltd filing is on SEC EDGAR ↗. 8-K briefs of other companies →